Pretreatment NC FLT3 TKD mutations in patients treated with gilteritinib
| Subject no. . | Initial dose, mg/d . | Age/sex/race/weight . | CR/CRh . | Best overall response . | Cytogenetic risk status . | Specimen type . | Blast, % . | Mutation . | VAF, % . |
|---|---|---|---|---|---|---|---|---|---|
| 5 | 80 | 66 y/female/W/93.1 kg | No | NR | Unfavorable: del7q | Bone marrow | 91 | p.N676K | 3.56 |
| p.D835H | 36.48 | ||||||||
| 40 | 120 | 51 y/female/W/42.1 kg | No | NR | Unfavorable: complex | Bone marrow | N/A | ITD | 8.04 |
| ITD | 35.34 | ||||||||
| p.Y842C | 43.75 | ||||||||
| 69 | 200 | 67 y/male/W/87.5 kg | No | NR | Intermediate: normal | Blood | 81 | ITD | 73.53 |
| p.M837K | 0.78 | ||||||||
| 101 | 300 | 24 y/male/W/67.4 kg | No | PR | Intermediate: normal | Bone marrow | 95 | ITD | 54.21 |
| p.H721Y | 46.42 | ||||||||
| 112 | 300 | 65 y/male/W/78.2 kg | No | NR | Unfavorable: complex | Bone marrow | 74 | p.N676K | 0.86 |
| p.D835V | 0.93 | ||||||||
| 133 | 200 | 67 y/male/W/59.4 kg | No | PR | Intermediate: +8 | Bone marrow | 62 | p.N841Y | 32.97 |
| 143 | 200 | 79 y/female/W/66.0 kg | No | NR | Unfavorable: del5q, Unfavorable: del7q | Bone marrow | 89 | ITD | 2.25 |
| ITD | 11.52 | ||||||||
| ITD | 13.66 | ||||||||
| p.N841T | 0.94 | ||||||||
| 176 | 300 | 75 y/female/W/66.1 kg | No | NR | Intermediate: normal | Bone marrow | 56 | p.M737I | 20.51 |
| 210 | 80 | 76 y/male/O/72.8 kg | No | NE | Favorable: t(8;21) | Bone marrow | 21 | ITD | 0.92 |
| ITD | 1.24 | ||||||||
| p.G757E | 51.34 | ||||||||
| 216 | 120 | 64 y/male/W/117.1 kg | No | NR | Intermediate: normal | Bone marrow | 57 | p.D839E | 1.22 |
| p.M837K | 1.26 |
| Subject no. . | Initial dose, mg/d . | Age/sex/race/weight . | CR/CRh . | Best overall response . | Cytogenetic risk status . | Specimen type . | Blast, % . | Mutation . | VAF, % . |
|---|---|---|---|---|---|---|---|---|---|
| 5 | 80 | 66 y/female/W/93.1 kg | No | NR | Unfavorable: del7q | Bone marrow | 91 | p.N676K | 3.56 |
| p.D835H | 36.48 | ||||||||
| 40 | 120 | 51 y/female/W/42.1 kg | No | NR | Unfavorable: complex | Bone marrow | N/A | ITD | 8.04 |
| ITD | 35.34 | ||||||||
| p.Y842C | 43.75 | ||||||||
| 69 | 200 | 67 y/male/W/87.5 kg | No | NR | Intermediate: normal | Blood | 81 | ITD | 73.53 |
| p.M837K | 0.78 | ||||||||
| 101 | 300 | 24 y/male/W/67.4 kg | No | PR | Intermediate: normal | Bone marrow | 95 | ITD | 54.21 |
| p.H721Y | 46.42 | ||||||||
| 112 | 300 | 65 y/male/W/78.2 kg | No | NR | Unfavorable: complex | Bone marrow | 74 | p.N676K | 0.86 |
| p.D835V | 0.93 | ||||||||
| 133 | 200 | 67 y/male/W/59.4 kg | No | PR | Intermediate: +8 | Bone marrow | 62 | p.N841Y | 32.97 |
| 143 | 200 | 79 y/female/W/66.0 kg | No | NR | Unfavorable: del5q, Unfavorable: del7q | Bone marrow | 89 | ITD | 2.25 |
| ITD | 11.52 | ||||||||
| ITD | 13.66 | ||||||||
| p.N841T | 0.94 | ||||||||
| 176 | 300 | 75 y/female/W/66.1 kg | No | NR | Intermediate: normal | Bone marrow | 56 | p.M737I | 20.51 |
| 210 | 80 | 76 y/male/O/72.8 kg | No | NE | Favorable: t(8;21) | Bone marrow | 21 | ITD | 0.92 |
| ITD | 1.24 | ||||||||
| p.G757E | 51.34 | ||||||||
| 216 | 120 | 64 y/male/W/117.1 kg | No | NR | Intermediate: normal | Bone marrow | 57 | p.D839E | 1.22 |
| p.M837K | 1.26 |
CR, complete remission; CRh, complete remission with partial hematological recovery; Cri, complete remission with incomplete hematological recovery; CRp, complete remission with incomplete platelet recovery; EOT, end of treatment; N/A, not available; NE, not evaluable; NR, no response; O, other; PR, partial response; VAF, variant frequency; W, white.